REVIEW PAPER
Juvenile-onset recurrent respiratory papillomatosis
1
Department of Otolaryngology, Head and Neck Surgery, Wroclaw Medical University, Wrocław, Poland
Submission date: 2025-03-19
Acceptance date: 2025-05-31
Publication date: 2025-06-01
Corresponding author
Aleksandra Wojno
Aleksandra Wojno, Department of Otolaryngology, Head and Neck Surgery, Medical University, 213 Borowska St., 50-556 Wrocław, Polan
Aleksandra Wojno, Department of Otolaryngology, Head and Neck Surgery, Medical University, 213 Borowska St., 50-556 Wrocław, Polan
Pediatr Pol 2025;61(2):173-176
KEYWORDS
recurrent respiratory papillomatosisHPVpapillomapaediatric diseasejuvenile-onset recurrent respiratory papillomatosis
TOPICS
ABSTRACT
Juvenile-onset recurrent respiratory papillomatosis (JORRP) is a rare disease caused by an infection of human papillomavirus (HPV) – most commonly types 6 and 11. These types of HPV are vaccine-preventable. The virus is transmitted vertically. Human papillomavirus can alter immune response by reducing interferon-γ and interleukin-2 expression. Most JORRP patients develop symptoms before the age of 5 years. In severe cases this disease can lead to airway obstruction or malignant transformation. The treatment primarily consists of surgery as well as intralesional or systemic bevacizumab therapy or adjuvant therapy. Patients who develop symptoms at a younger age usually need more surgeries than older patients with JORRP. To reduce the incidence rate of JORRP, HPV vaccination is recommended.
REFERENCES (38)
1.
Bertino G, Pedretti F, Mauramati S, et al. Recurrent laryngeal papillomatosis: multimodal therapeutic strategies. Literature review and multicentre retrospective study. Acta Otorhinolaryngol Ital 2023; 43: S111-22.
2.
Lawlor C, Balakrishnan K, Bottero S, et al. International Pediatric Otolaryngology Group (IPOG): juvenile-onset recurrent respiratory papillomatosis consensus recommendations. Int J Pediatr Otorhinolaryngol 2020; 128: 109697.
3.
Lepine C, Leboulanger N, Badoual C. Juvenile onset recurrent respiratory papillomatosis: what do we know in 2024 ? Tumour Virus Res 2024; 17: 200281.
4.
Benedict JJ, Derkay CS. Recurrent respiratory papillomatosis: a 2020 perspective. Laryngoscope Investig Otolaryngol 2021; 6: 340-345.
5.
Ryan MA, Leu GR, Upchurch PA, Tunkel DE, Walsh JM, Boss EF. Systemic bevacizumab (avastin) for juvenile-onset recurrent respiratory papillomatosis: a systematic review. Laryngoscope 2021; 131: 1138-1146.
6.
Li SL, Wang W, Zhao J, Zhang FZ, Zhang J, Ni X. A review of the risk factors associated with juvenile-onset recurrent respiratory papillomatosis: genetic, immune and clinical aspects. World J Pediatr 2022; 18: 75-82.
7.
Amiling R, Meites E, Querec TD, et al. Juvenile-onset recurrent respiratory papillomatosis in the United States, epidemiology and HPV types-2015-2020. J Pediatric Infect Dis Soc 2021; 10: 774-781.
8.
Wolf J, Kist LF, Pereira SB, et al. Human papillomavirus infection: epidemiology, biology, host interactions, cancer development, prevention, and therapeutics. Rev Med Virol 2024; 34: e2537.
9.
Nantel É, Mayrand MH, Audibert F, et al. Association between the mode of delivery and vertical transmission of human papillomavirus. Viruses 2024; 16: 303.
10.
Kurita T, Chitose S, Sato K, et al. Pathological mechanisms of laryngeal papillomatosis based on laryngeal epithelial characteristics. Laryngoscope Investig Otolaryngol 2019; 4: 89-94.
11.
Lépine C, Voron T, Berrebi D, et al. Juvenile-onset recurrent respiratory papillomatosis aggressiveness: in situ study of the level of transcription of HPV E6 and E7. Cancers (Basel) 2020; 12: 1-12.
12.
Conrady MC, Suarez I, Gogl G, et al. Structure of high-risk papillomavirus 31 E6 oncogenic protein and characterization of E6/E6AP/p53 complex formation. J Virol 2020; 95: e00730-20.
13.
Chen L, Hu H, Pan Y, et al. The role of HPV11 E7 in modulating STING-dependent interferon β response in recurrent respiratory papillomatosis. J Virol 2024; 98: e0192523.
14.
Khreefa Z, Isaac V, Poulik J, et al. Correlation between E6 and E7 oncogenes and malignant transformation of laryngeal papillomatosis (LP) with human papillomavirus (HPV) in pediatric population. Fetal Pediatr Pathol 2021; 40: 290-294.
15.
Sarafoleanu C, Lapicus G, Lupu AI, Budu V. Difficulties in the treatment of recurrent juvenile laryngeal papillomatosis associated with pemphigus vulgaris. Romanian J Rhinol 2020; 10: 38-44.
16.
Wang W, Xi Y, Li S, et al. Restricted recruitment of NK cells with impaired function is caused by hpv-driven immunosuppressive microenvironment of papillomas in aggressive juvenile-onset recurrent respiratory papillomatosis patients. J Virol 2022; 96.
17.
Coordes A, Grund D, Mainka A, et al. [Recurrent laryngeal papillomatosis]. HNO 2023; 71: 77-82.
18.
Mudd P, Wikner E, Rana MS, Zalzal G. Presenting symptom as a predictor of clinical course in juvenile onset recurrent respiratory papillomatosis. Laryngoscope 2021; 131: 1670-1675.
19.
Labedz G, Scatolini ML, Ruvinsky S, Rodriguez HA. Factors related to extralaryngeal spread in juvenile recurrent respiratory papillomatosis. Laryngoscope 2021; 131: 1652-1656.
20.
Hamdi O, Dome J, Zalzal G, Preciado D. Systemic bevacizumab for end-stage juvenile recurrent respiratory papillomas: a case report. Int J Pediatr Otorhinolaryngol 2020; 128: 109706.
21.
Bedard MC, de Alarcon A, Kou YF, et al. HPV strain predicts severity of juvenile-onset recurrent respiratory papillomatosis with implications for disease screening. Cancers (Basel) 2021; 13: 2556.
22.
Yang Q, Li Y, Ma L, et al. Long-term outcomes of juvenile onset recurrent respiratory papillomatosis with pulmonary involvement. Laryngoscope 2021; 131: EE2277-E2283.
23.
Seedat RY. Juvenile-onset recurrent respiratory papillomatosis diagnosis and management – a developing country review. Pediatric Health Med Ther 2020; 11: 39.
24.
Alves Melo IM, Pereira Viana MR, Pupin B, Bhattacharjee TT, de Azevedo Canevari R. PCR-RFLP and FTIR-based detection of high-risk human papilloma virus for cervical cancer screening and prevention. Biochem Biophys Rep 2021; 26: 100993.
25.
Williams J, Kostiuk M, Biron VL. Molecular detection methods in HPV-related cancers. Front Oncol 2022; 12: 864820.
26.
Ivancic R, Iqbal H, deSilva B, Pan Q, Matrka L. Current and future management of recurrent respiratory papillomatosis. Laryngoscope Investig Otolaryngol 2018; 3: 22-34.
27.
Xiao Y, Zhang X, Ma L, Wang J. Long-term outcomes of juvenile-onset recurrent respiratory papillomatosis. Clin Otolaryngol 2021; 46: 161-167.
28.
Rashid M, Saleem H, Karim MN, Najam A, Abdullah A, Haneef J. Role Of CO2 laser & microdebrider in the treatment of juvenile onset recurrent respiratory papillomatosi. J Pak Med Assoc 2023; 73: 1370-1373.
29.
Zeleník K, Komínek P, Staníková L, Formánek M. Local bevacizumab treatment of juvenile-onset respiratory papillomatosis might induce multiple tracheal pyogenic granulomas. Laryngoscope 2021; 131: E518-520.
30.
Enrique OH, Eloy SH, Adrian TP, Perla V. Systemic bevacizumab as adjuvant therapy for recurrent respiratory papillomatosis in children: a series of three pediatric cases and literature review. Am J Otolaryngol 2021; 42: 103126.
31.
Rogers DJ, Ojha S, Maurer R, Hartnick CJ. Use of adjuvant intralesional bevacizumab for aggressive respiratory papillomatosis in children. JAMA Otolaryngol Head Neck Surg 2013; 139: 496-501.
32.
Wang Y, Dai PD, Zhang TY. Experimental research on the therapeutic effect of MMR vaccine to juvenile-onset recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol 2019; 276: 801-803.
33.
Schindele A, Al-Sabtti S, Olofsson K. Human papilloma virus (HPV) vaccination is associated with reduced number of surgical treatments, an observational study on recurrent respiratory papillomatosis in Northern Sweden. Acta Otolaryngol 2024; 144: 71-75.
34.
Meites E, Stone L, Amiling R, et al. Significant declines in juvenile-onset recurrent respiratory papillomatosis following human papillomavirus (HPV) vaccine introduction in the United States. Clin Infect Dis 2021; 73: 885-890.
35.
Goon P, Sauzet O, Schuermann M, et al. Recurrent respiratory papillomatosis (RRP)-meta-analyses on the use of the HPV vaccine as adjuvant therapy. NPJ Vaccines 2023; 8: 49.
36.
Balai E, Dronkers EAC, Al Yaghchi C, Gujral D, Sandhu G, Iacovidou A. Adjuvant treatments for recurrent respiratory papillomatosis: a descriptive review and proposed management guideline in adults. J Laryngol Otol 2024; 138: 1133-1143.
37.
Ponduri A, Azmy MC, Axler E, et al. The efficacy of human papillomavirus vaccination as an adjuvant therapy in recurrent respiratory papillomatosis. Laryngoscope 2023; 133: 2046-2054.
38.
Rosenberg T, Philipsen BB, Mehlum CS, et al. Therapeutic use of the human papillomavirus vaccine on recurrent respiratory papillomatosis: a systematic review and meta-analysis. J Infect Dis 2019; 219: 1016-1425.
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
